Entrada Therapeutics, Inc. Common Stock (TRDA) Stock
Fundamentals
Source: third-party data provider, as of October 14, 2026
Compare with TRDA
Recent news

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
TRDA

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
TRDA

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
TRDA

Entrada's Duchenne drug shown to improve muscle function in early trial
Entrada's Duchenne drug shown to improve muscle function in early trial
TRDA
Technical indicators
- RSI 14
- 27.76
- MACD 12/26/9
- -0.43
- EMA 9 of MACD
- -0.36
- MACD histogram
- -0.07
- SMA 50
- $6.73
- Price below SMA 50
- EMA 50
- $6.50
- Price below EMA 50
- SMA 200
- $9.14
- Price below SMA 200
- EMA 200
- $8.45
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
TRDA

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
TRDA

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
TRDA

Entrada's Duchenne drug shown to improve muscle function in early trial
Entrada's Duchenne drug shown to improve muscle function in early trial
TRDA

Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
TRDA

New Strong Buy Stocks for December 30th
New Strong Buy Stocks for December 30th
TRDA

Best Momentum Stocks to Buy for July 9th
Best Momentum Stocks to Buy for July 9th
TRDA

New Strong Buy Stocks for July 9th
New Strong Buy Stocks for July 9th
TRDA

Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy
Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy
TRDA

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
TRDA
About Entrada Therapeutics, Inc. Common Stock
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Dipal Doshi | CEO & Director | 1976 |
| Mr. Nathan J. Dowden | President & COO | 1971 |
| Mr. Kory James Wentworth CPA | CFO & Treasurer | 1979 |
| Dr. Natarajan Sethuraman Ph.D. | President of Research & Development | 1962 |
| Dr. Jared Cohen J.D., Ph.D. | General Counsel | — |
| Ms. Karla MacDonald | Chief Corporate Affairs Officer | — |
| Mr. Kevin Healy Ph.D. | Senior Vice President of Regulatory Affairs | — |
| Sandeep Basnet | Head of Information Technology | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 14, 2026
Technical indicators
- RSI 14
- 27.76
- MACD 12/26/9
- -0.43
- EMA 9 of MACD
- -0.36
- MACD histogram
- -0.07
- SMA 50
- $6.73
- Price below SMA 50
- EMA 50
- $6.50
- Price below EMA 50
- SMA 200
- $9.14
- Price below SMA 200
- EMA 200
- $8.45
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.2 | +6.5 | -10.5 | -2.9 | -10.2 | -14.4 |



